These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10952478)

  • 21. Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment With bupropion.
    Güzey C; Norström A; Spigset O
    Ther Drug Monit; 2002 Jun; 24(3):436-7. PubMed ID: 12021638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation: a study of mutations CYP2D6*3 and CYP2D6*4.
    Monek O; Paintaud G; Bechtel Y; Miguet JP; Mantion G; Bechtel PR
    Eur J Clin Pharmacol; 1998 Mar; 54(1):47-52. PubMed ID: 9591930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status.
    Barclay ML; Sawyers SM; Begg EJ; Zhang M; Roberts RL; Kennedy MA; Elliott JM
    Pharmacogenetics; 2003 Oct; 13(10):627-32. PubMed ID: 14515061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CYP2D6 Genotype Phenotype Discordance Due to Drug-Drug Interaction.
    Monte AA; West K; McDaniel KT; Flaten HK; Saben J; Shelton S; Abdelmawla F; Bushman LR; Williamson K; Abbott D; Anderson PL
    Clin Pharmacol Ther; 2018 Nov; 104(5):933-939. PubMed ID: 29882961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
    Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
    Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.
    Hertz DL; Snavely AC; McLeod HL; Walko CM; Ibrahim JG; Anderson S; Weck KE; Magrinat G; Olajide O; Moore S; Raab R; Carrizosa DR; Corso S; Schwartz G; Peppercorn JM; Evans JP; Jones DR; Desta Z; Flockhart DA; Carey LA; Irvin WJ
    Br J Clin Pharmacol; 2015 Nov; 80(5):1122-30. PubMed ID: 25907378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline.
    Davies BJ; Herbert MK; Coller JK; Somogyi AA; Milne RW; Sallustio BC
    Br J Clin Pharmacol; 2008 Mar; 65(3):347-54. PubMed ID: 17875193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
    Zanger UM; Raimundo S; Eichelbaum M
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):23-37. PubMed ID: 14618296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients.
    Dandara C; Masimirembwa CM; Magimba A; Sayi J; Kaaya S; Sommers DK; Snyman JR; Hasler JA
    Eur J Clin Pharmacol; 2001 Apr; 57(1):11-7. PubMed ID: 11372584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of CYP2D6*3 and 2D6*4 allelic variants by PCR-restriction fragment length polymorphism.
    Topić E; Stefanović M; Nikolić V; Zoricić I; Ivanisević AM; Zuntar I
    Clin Chem Lab Med; 1998 Aug; 36(8):655-8. PubMed ID: 9806480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting.
    McElroy S; Sachse C; Brockmoller J; Richmond J; Lira M; Friedman D; Roots I; Silber BM; Milos PM
    AAPS PharmSci; 2000; 2(4):E33. PubMed ID: 11741249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
    Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
    J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
    Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
    Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polymorphisms and phenotypic analysis of cytochrome P450 2D6 in the Tibetan population.
    Jin TB; Ma LF; Zhang JY; Yuan DY; Sun Q; Zong TY; Geng TT; Cui YL; Kang LL; Chen C
    Gene; 2013 Sep; 527(1):360-5. PubMed ID: 23644254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors.
    Gressier F; Verstuyft C; Hardy P; Becquemont L; Corruble E
    J Neural Transm (Vienna); 2015 Jan; 122(1):35-42. PubMed ID: 25047911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CYP2D6 extensive, intermediate, and poor phenotypes and genotypes in a Polish population.
    Niewinski P; Orzechowska-Juzwenko K; Hurkacz M; Rzemislawska Z; Jaźwinska-Tarnawska E; Milejski P; Forkasiewicz Z
    Eur J Clin Pharmacol; 2002 Nov; 58(8):533-5. PubMed ID: 12536989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
    Dorado P; Cáceres MC; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
    Biotechniques; 2005 Oct; 39(4):571-4. PubMed ID: 16235570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.
    Lefebvre J; Poirier L; Poirier P; Turgeon J; Lacourciere Y
    Br J Clin Pharmacol; 2007 May; 63(5):575-82. PubMed ID: 17094780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships.
    Chou WH; Yan FX; Robbins-Weilert DK; Ryder TB; Liu WW; Perbost C; Fairchild M; de Leon J; Koch WH; Wedlund PJ
    Clin Chem; 2003 Apr; 49(4):542-51. PubMed ID: 12651805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Side effects associated with ultrarapid cytochrome P450 2D6 genotype among women with early stage breast cancer treated with tamoxifen.
    Rolla R; Vidali M; Meola S; Pollarolo P; Fanello MR; Nicolotti C; Saggia C; Forti L; Agostino FD; Rossi V; Borra G; Stratica F; Alabiso O; Bellomo G
    Clin Lab; 2012; 58(11-12):1211-8. PubMed ID: 23289191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.